

Special Issue

Vaccines Safety during Emerging Infections and Issues of Special Populations and Minority Groups

Message from the Guest Editors

Objectives:

- How to communicate vaccine-related safety issues;
- Policy making and regulations related to vaccine safety;
- How to report vaccine-related pharmacovigilance;
- How to manage vaccine side effects and adverse reactions;
- Companies versus labs versus government communications regarding vaccine safety.

Examples of special populations: Elderly; infants; children; patients with genetic problems; patients with autism; pregnancy; patients with cancer; patients with disabilities; patients with organ damage; patients with comorbidities. **Targeted emerging infections:**

- SARS;
- COVID-19;
- Nipah virus;
- Dengue virus;
- Ebola virus;
- Zika virus;
- Hepatitis;
- Monkeypox virus.

Guest Editors

Dr. Ahmed Ibrahim Fathelrahman

Dr. Elmoubashar Farag

Dr. Mansour Adam Mahmoud

Dr. Asim Ahmed Elnour

Deadline for manuscript submissions

closed (31 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/154738

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).